|
|
|
Galecto Announces Clinical Collaboration with Roche for Ph 2 Trial of GB1211 in Combination with Atezolizumab in 1L NSCLC
“Our galectin-3 asset, GB1211, has shown compelling anti-cancer effects in preclinical models, specifically in NSCLC tumors high in galectin-3 and resistant to anti-PD-1/-L1,” said Dr. Hans Schambye, CEO of Galecto. “Galectin-3 inhibition has the potential to increase both T-cell function as a single agent and the efficacy of check-point inhibitors in NSCLC patients with high galectin-3 expression. We look forward to initiating our phase 2a combination study of GB1211 in NSCLC during the first half of 2022 and anticipate topline data from this trial in mid-2023.”
|
|
Stingthera and Merck to Evaluate SNX281 in Combination With KEYTRUDA® (pembrolizumab) in Certain Patients with Advanced Solid Tumors and Lymphoma
"We are pleased to collaborate with Merck to evaluate SNX281 in combination with KEYTRUDA as treatment for people with solid tumors or lymphoma who have relapsed on or have become refractory to prior immune checkpoint therapy, as these are patients for which there are limited treatment options available and their overall survival remains low," said Humphrey Gardner, M.D., F.C.A.P., chief medical officer, Stingthera. "We look forward to further evaluating the potential clinical utility of this combination, in an effort to improve outcomes for patients with a number of different cancers.”
|
|
|
Prilenia Therapeutics has raised $133.5M for going after Huntington's disease
Prilenia Therapeutics is a Dutch startup, has raised $133.5M thus far and is backed by a group of well-respected investors. The company’s lead asset Pridopidone failed the previous Phase II trial endpoint at Teva. Michael Hayden, MBChB, PhD., ex- R&D chief for Teva, who he led the development of ~35 new products towards approval in several major markets, predominantly in CNS. He took Pridopidone with him and left Teva in 2017. Together with a highly experienced team with a track record of success, Hayden founded Prilenia as a clinical-stage biotech company. Now, Prilenia is a global company with offices in The Netherlands, Israel, and The U.S.
Pridopidine is a highly selective and potent Sigma-1 Receptor (S1R) agonist with an established safety profile. Pridopidine is orally administered with therapeutic potential in HD, ALS, and other neurodegenerative diseases and neurodevelopmental disorders such as Rett and Fragile-X. The Drug is now expected to read out topline Phase III results in 2023 and is now aimed at the right endpoint - by Total Functional Capacity (TFC) in a prior clinical study. Furthermore, pridopidine was selected from an international competition of over 30 innovative new drugs for inclusion in the first ALS platform trial, led by the Healey Center for ALS at Massachusetts General Hospital. Following the Roche/Ionis bust and another flop from Wave Life Sciences earlier this year, pridopidine is now the most advanced clinical asset in Huntington’s out there.
|
|
Antios Therapeutics Raises total of $171M for their hep B candidate
Antios Therapeutics, a clinical-stage biopharmaceutical company developing innovative therapies to treat and cure chronic hepatitis B virus (HBV), announced the successful closing of a $75M in Series B-1 financing. This concludes successful fundraising run with $25M at Series A and $96M at Series B. The financing round was co-led by young investment firm GordonMD Global Investments.
The proceeds from this financing will be used to advance the clinical development of ATI-2173, Antios’ lead Phase 2b clinical candidate. ATI-2173 is the only Active Site Polymerase Inhibitor Nucleotide (ASPIN) in clinical development and has the potential, if approved, to become the cornerstone of a curative, once-daily HBV therapy. Pre-clinical data to date for ATI-2173, alone or combined with tenofovir disoproxil fumarate (TDF), indicate the potential for sustained HBV DNA suppression off treatment, unique among approved nucleosides and investigational anti-HBV therapies.
“Antios’ unique approach to developing potentially curative therapies for HBV and other viral diseases, and the strong results from the Phase 1b clinical trial data of ATI-2173, are impressive,” said Craig Gordon, MD, Founder, CEO, and CIO of GordonMD Global Investments. “We believe in the mission that Antios’ management and clinical teams are driving forward and are excited to be a part of their next phase of growth.” As part of the funding announcement, Antios also announced that Dr. Gordon will join the Antios Board of Directors.
|
|
Click here for more on mergers, acquisition and business news
|
|
Disclaimer
The editors take care to share authentic information. In case of any discrepancies please write to medness.newsletter@gmail.com
The sponsors do not have any influence on the nature or kind of the news/analysis reported in MedNess. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of Medness. Examples of analysis performed within this article are only examples. They should not be utilized in real-world analytic products as they are based only on very limited and dated open source information. Assumptions made within the analysis are not reflective of the position of anyone volunteering or working for Medness. This blog is strictly for news and information. It does not provide medical advice, diagnosis or treatment nor investment suggestions. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or another qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
|
|
|
|
|
|
|